Long-Term Effects of Haloperidol on Severely Emotionally Disturbed Children

1971 ◽  
Vol 5 (4) ◽  
pp. 296-300 ◽  
Author(s):  
G. H. Wong ◽  
R. J. Cock
Keyword(s):  
Emotional Disorders ◽  
Emotionally Disturbed ◽  
Statistical Significance ◽  
Double Blind Study ◽  
Long Term Effects ◽  
Double Blind ◽  
Diagnostic Categories ◽  
Learning Tasks ◽  
Severely Emotionally Disturbed

A controlled, double-blind study of haloperidol in 30 children suffering from severe emotional disorders was attempted. Toxic and side-effects and reduction of symptoms were observed over a prolonged period of medication. A battery of tests was designed to study any adverse effects on development and learning processes. The conclusions reached indicated that at an overall level and in terms of diagnostic categories, no statistical significance was established when compared with placebo. However, haloperidol is significantly superior to placebo in ameliorating particular symptoms, is a relatively safe drug, and it did not impair intellectual functioning and learning tasks.

116 A double-blind study of three sodium intakes, and the long- term effects of sodium restriction in essential hypertension

1988 ◽  
Vol 6 (4) ◽  
pp. S742 ◽  
Author(s):  
Nirmala D. Markandu ◽  
Donald R.J. Singer ◽  
Giuseppe A. Sagnella ◽  
Francesco P. Cappuccio ◽  
A. L. Sugden ◽  
...  
Keyword(s):  
Essential Hypertension ◽  
Blind Study ◽  
Double Blind Study ◽  
Sodium Restriction ◽  
Long Term Effects ◽  
Double Blind

The long-term effects of homeopathic treatment of chronic headaches: one year follow-up and single case time series analysis

2001 ◽  
Vol 90 (02) ◽  
pp. 63-72 ◽  
Author(s):  
H Walach ◽  
T Lowes ◽  
D Mussbach ◽  
U Schamell ◽  
W Springer ◽  
...  
Keyword(s):  
Time Series ◽  
Single Case ◽  
Double Blind Study ◽  
Long Term Effects ◽  
Double Blind ◽  
Homeopathic Treatment ◽  
Chronic Headaches ◽  
One Year

AbstractLittle is known about long-term effects of homeopathic treatment. Following a double-blind, placebo controlled trial of classical homeopathy in chronic headaches, we conducted a 1-year observational study of 18 patients following the double-blind phase, and a complete follow-up study of all trial participants. Eighteen patients received free treatment for daily diary data (frequency, intensity, duration of headaches) over the course of 1 y. All patients enrolled in the double-blind study were sent a 6-week headache diary, a follow-up questionnaire, a personality inventory and a complaint list. Eighty-seven, of the original 98 patients enrolled returned questionnaires, 81 returned diaries. There was no additional change from the end of the trial to the one-year follow-up. The improvement seen at the end of the 12-week trial was stable after 1 y. No differential effects according to treatment after the trial could be seen. Patients with no treatment following the trial had the most improvement after 1 y. Five of 18 patients can be counted responders according to ARIMA analysis of single-case time-series. Patients with double diagnoses and longer treatment duration tended to have clearer improvements than the rest of the patients. Approximately 30% of patients in homeopathic treatment will benefit after 1 y of treatment. There is no indication of a specific, or of a delayed effect of homeopathy.

DOUBLE-BLIND STUDY OF THREE SODIUM INTAKES AND LONG-TERM EFFECTS OF SODIUM RESTRICTION IN ESSENTIAL HYPERTENSION

The Lancet ◽  
1989 ◽  
Vol 334 (8674) ◽  
pp. 1244-1247 ◽  
Author(s):  
G.A. Macgregor ◽  
G.A. Sagnella ◽  
N.D. Markandu ◽  
D.R.J. Singer ◽  
F.P. Cappuccio
Keyword(s):  
Essential Hypertension ◽  
Blind Study ◽  
Double Blind Study ◽  
Sodium Restriction ◽  
Long Term Effects ◽  
Double Blind

scholarly journals Acute and Long-term Effects of Saxagliptin on a Set of Cardiovascular Targets Measured at Fasting and Post-prandially in Obese Patients With Impaired Glucose Tolerance: a Randomized, Placebo-controlled, Double-blind Study

2020 ◽  
Author(s):  
Amel Rezki ◽  
Emmanuel Cosson ◽  
Marinos Fysekidis ◽  
Sabrina Chiheb ◽  
Eric Vicaut ◽  
...  
Keyword(s):  
Glucose Tolerance ◽  
Impaired Glucose Tolerance ◽  
Augmentation Index ◽  
Double Blind Study ◽  
Vagal Activity ◽  
Large Set ◽  
Obese Patients ◽  
Long Term Effects ◽  
Double Blind

Abstract Background: Studies of dipeptidyl peptidase inhibitors (DPP4is) report heterogeneous effects on cardiovascular targets in type 2 diabetes. Little is known about the cardiovascular effects of DPP4is in patients with impaired glucose tolerance (IGT) in particular during the post-prandial state. Methods: In this randomized, placebo-controlled, double-blind, single-center pilot study, we included obese individuals with IGT. Participants were randomized to receive for 12 weeks either saxagliptin 5mg a day or placebo. They were explored non-invasively before and after a standardized breakfast for biological markers; microcirculatory blood flow at baseline and after transcutaneous administration of acetylcholine (Periflux System 5000® PERIMED); post-occlusive digital reactive hyperhemia (Endopat2000®); pulse wave velocity, augmentation index, central pulse pressure and subendocardial viability ratio (Sphygmocor®); cardiac hemodynamic parameters and cardiovascular autonomic nervous system activity (Task force monitor®). Results: We investigated 24 individuals (mean body mass index 36.8±4.8 kg/m2, hypertension 33.3%). The results of all the investigations were similar after breakfast in the two groups at Visit 1 (acute post-prandial effects, after the first tablet) and Visit 2 (long-term post-prandial effects), and at fasting at Visit 1 and 2 (long-term effects, after 12 weeks of treatment). Only at Visit 2 the decrease in cardiac vagal activity occurring after breakfast was more sustained in the saxagliptin group than in the placebo group (interaction between treatment and time effect: p=0.016).Conclusion: In obese patients with IGT, among the large set of cardiovascular parameters we measured in the fasting and post-prandial state, the unique change induced by saxagliptin consisted in a more marked post-prandial depression of vagal activity. Clinical Trial Registration number: NCT01521312

scholarly journals Effects of growth hormone treatment on the leptin system and on energy expenditure in abdominally obese men

1998 ◽  
pp. 408-414 ◽  
Author(s):  
C Karlsson ◽  
K Stenlof ◽  
G Johannsson ◽  
P Marin ◽  
P Bjorntorp ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Energy Expenditure ◽  
Double Blind Study ◽  
Mrna Levels ◽  
Long Term Effects ◽  
Gh Treatment ◽  
Double Blind ◽  
Serum Leptin ◽  
Leptin System

The present study has examined the short- and long-term effects of growth hormone (GH) treatment on the leptin system and energy expenditure. Thirty male individuals with abdominal obesity were randomised to GH or placebo treatment in a 9-month, double-blind study. The dose of GH was 9.5 microg/kg, administered subcutaneously every evening. Serum leptin concentrations were measured by a human leptin RIA. Total RNA was isolated from adipose tissue biopsies and leptin mRNA levels were determined by a semi-quantitative reverse transcriptase-PCR assay. Body composition was determined by potassium-40 and the basal metabolic rate (BMR) was measured by a computerised, ventilated, open-hood system. As compared with placebo, an overall decrease in serum leptin concentrations as assessed by the area under the curve (AUC) (P < 0.05) and an increase in BMR (AUC, P < 0.05) were observed during GH treatment. The overall GH-induced changes were due to marked changes in serum leptin concentrations and BMR after 6 weeks of treatment. After 9 months of GH treatment there was a significant reduction in body fat (BF) while serum leptin concentrations and BMR did not differ from baseline values. Leptin mRNA levels did not change over the study period. We speculate that long-term GH treatment induces a new energy balance steady state with decreased BF stores. The effects of GH on the leptin system is suggested to be of importance for the maintenance of a lower BF mass.

Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: A double-blind study

1991 ◽  
Vol 125 (4) ◽  
pp. 385-391 ◽  
Author(s):  
J. A. Verhelst ◽  
A. L. Froud ◽  
R. Touzel ◽  
J. A. H. Wass ◽  
G. M. Besser ◽  
...  
Keyword(s):  
Dopamine Agonist ◽  
Adverse Reactions ◽  
Double Blind Study ◽  
Long Term Effects ◽  
Double Blind ◽  
Once Daily ◽  
Long Acting ◽  
To Receive ◽  
Blind Manner

Abstract. Quinagolide (CV 205-502, Sandoz), an octahydrobenzo (g) quinoline, is a new non-ergot dopamine agonist which has specific D2 receptor activity and a long half-life, making it suitable for once-daily treatment. Recent uncontrolled reports have suggested that quinagolide may be successfully used for the clinical management of hyperprolactinemia with fewer adverse reactions than bromocriptine. This study is the first to compare quinagolide in a double-blind manner with bromocriptine, given only once-daily instead of the usual multidose regimen. In the first phase we compared, in 7 hyperprolactinemic patients, the effects over 24 h of a single oral dose of 0.05 mg quinagolide with 2.5 mg bromocriptine. Compared with placebo, both bromocriptine and quinagolide showed potent PRL-inhibiting and GH-releasing effects, with comparable effects at 24 h; no significant changes were observed in TSH, LH, FSH or cortisol. Twelve hyperprolactinemic patients were then randomized to receive either once-daily bromocriptine or quinagolide in incremental doses for a period of six months. Both drugs were found to be equally effective, and no differences were seen either in adverse reactions or PRL levels during repeated diurnal sampling. We therefore conclude that quinagolide and bromocriptine are therapeutically equivalent in long-term use, and both are equally effective when given once a day. However, some patients intolerant of bromocriptine may respond better to quinagolide, and vice versa.

The Long-Term Effects of Homeopathic Treatment of Chronic Headaches: 1 Year Follow Up

Cephalalgia ◽  
2000 ◽  
Vol 20 (9) ◽  
pp. 835-837 ◽  
Author(s):  
H Walach ◽  
T Lowes ◽  
D Mussbach ◽  
U Schamell ◽  
W Springer ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Double Blind Study ◽  
Long Term Effects ◽  
Delayed Effect ◽  
Double Blind ◽  
Homeopathic Treatment ◽  
Headache Diary ◽  
Chronic Headaches

Little is known about the long-term effects of homeopathic treatment. Following a double-blind, placebo-controlled trial of classical homeopathy in chronic headaches, we conducted a complete follow-up study of all trial participants. All patients enrolled in the double-blind study were sent a 6-week headache diary, a follow-up questionnaire. Eighty-seven of the original 98 patients enrolled returned questionnaires, 81 returned diaries. There was no additional change from the end of the trial to the 1-year follow up. The improvement seen at the end of the 12-week trial was stable after 1 year. No differential effects according to treatment after the trial could be seen. Patients with no treatment following the trial had the most improvement after 1 year. Approximately 30% of patients in homeopathic treatment will benefit after 1 year of treatment. There is no indication of a specific, or of a delayed effect of homeopathy.

Sign in / Sign up

Export Citation Format

Share Document